SCHEMBL20107340

SCHEMBL20107340

NCCOCCOCC(=O)NCCOCCOCC(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
EPOR P19235 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29172380 0.93 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHTTL3MBTL1ALDH1A1
SCHEMBL20107370 0.88 ALDH1A1 (0.53) SMN1; SMN2LMNAL3MBTL1ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL30145598 0.87 ALDH1A1 (0.51) SMN1; SMN2LMNAL3MBTL1ALDH1A1MAPK1
SCHEMBL13250748 0.85 ALDH1A1 (0.56) SMN1; SMN2LMNAL3MBTL1ALDH1A1MAPK1
SCHEMBL31235810 0.85 SMN1; SMN2 (0.56) SMN1; SMN2LMNAHTTL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL29193056 0.84 ALDH1A1 (0.54) SMN1; SMN2LMNAL3MBTL1ALDH1A1MAPK1
SCHEMBL20107206 0.83 LMNA (0.56) SMN1; SMN2LMNAL3MBTL1MAPT
SCHEMBL29040493 0.82 SMN1; SMN2 (0.83) SMN1; SMN2LMNAHTTL3MBTL1KEAP1
SCHEMBL30980590 0.82 SMN1; SMN2 (0.83) SMN1; SMN2LMNAHTTL3MBTL1KEAP1
SCHEMBL12196466 0.82 SMN1; SMN2 (0.83) SMN1; SMN2LMNAHTTL3MBTL1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018208-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2024-01-18 US disclosed
US-11732019-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors JANSSEN PHARMACEUTICA NV (BE) 2023-08-22 US disclosed
US-20210206822-A1 Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors JANSSEN PHARMACEUTICA NV (BE) 2021-07-08 US disclosed
US-10968264-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors JANSSEN PHARMACEUTICA NV (BE) 2021-04-06 US disclosed
US-10961293-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors JANSSEN PHARMACEUTICS NV (BE) 2021-03-30 US disclosed
US-20190345214-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2019-11-14 US disclosed
US-20180127476-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-10 US disclosed
WO-2018081367-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961293-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885
US-20210206822-A1 Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885
US-20240018208-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885
US-11732019-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885
US-20180127476-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885
US-10968264-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885
US-20190345214-A1 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS NPY4R, NPY5R, NPY1R SMN1; SMN2 4471/4885LMNA 3968/4885HTT 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.